Core Viewpoint - The appointment of Ju Lingke as the new Secretary of the Board at Sanli Pharmaceutical marks a significant transition in the company's governance, as she takes over from Zhang Qianfan, who held multiple roles and is now focusing on strategic and operational aspects of the company [1][9][18]. Group 1: Leadership Transition - Ju Lingke, a 34-year-old with a master's degree, has a clear career trajectory starting from financial institutions and moving to Sanli Pharmaceutical, where she has rapidly advanced from a financial manager to the Secretary of the Board in just over two years [4][6][7]. - Zhang Qianfan, the previous Secretary, had been in the role for nearly 11 years and will continue to serve as a director and vice chairman, indicating a strategic shift to allow him to focus on broader company operations [8][9]. - The company is undergoing a critical self-adjustment phase, and Ju Lingke's role will be pivotal in managing internal operations and external communications [1][18]. Group 2: Company Profile and Performance - Sanli Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine, with key products including various herbal formulations [20]. - The company's major shareholder, Zhang Hai, holds 40.91% of the shares, indicating a strong control over the company [21]. - Recent financial performance shows a decline, with revenue of 1.038 billion yuan for the first three quarters of 2025, down 28.24% year-on-year, and a net profit of 80.79 million yuan, down 58.39% year-on-year [23]. Group 3: Regulatory and Compliance Issues - Sanli Pharmaceutical has faced regulatory challenges, including a credit rating of "general" dishonesty due to past issues involving kickbacks related to its products [23][24]. - The company has engaged in a significant transaction with Hainan University, acquiring a candidate drug for Alzheimer's disease for 200 million yuan, which is seen as a strategic move into innovative pharmaceuticals [22].